Today we’re encouraged by new preliminary results from the LEGEND trial pivotal cohort evaluating our non-viral gene therapy in non-muscle invasive bladder cancer (NMIBC), which demonstrated improved complete response rates. View the press release: engene.com/detalimogene...

We’ve proud to be recognized as one of BioSpace’s 2026 Best Places to Work, celebrating the collaborative culture that drives our innovation in non-viral genetic medicines for people with urological cancers. Learn about this achievement: engene.com/engene-named...

Hear from Kate Chan, MD, MPH, our Executive Director & Urology Clinical Lead, on Pearls & Perspectives with Amy Pearlman, MD! She discusses the challenges for high-risk NMIBC patients who fail BCG and our LEGEND trial.

Listen here: bit.ly/m/enGene

enGene is excited for the 3️⃣ upcoming American Urological Association meetings, where we will be highlighting encore data from our LEGEND trial, evaluating our investigational, non-viral gene therapy for patients with #NMIBC.

See below for meeting details!

Join us in welcoming Hussein Sweiti, MD, MSc, as our Chief Medical Officer!

With 15+ years of experience and strong leadership skills, we’re confident he will be a great addition, especially as we advance our lead investigational candidate for patients with #NMIBC.

engene.com/engene-appoi...

Will you be at the South Central Section or Mid-Atlantic Section of the American Urological Association? Tune into one of several presentations from our team as we highlight the results from our ongoing LEGEND trial in patients with non-muscle invasive bladder cancer (#NMIBC).

We are proud to sponsor and attend the International Bladder Cancer Group Annual Retreat (#IBCG) this weekend.

Alongside fellow leaders in bladder cancer, we will join discussions on biomarkers and IBCG-BTx, sharing background on our novel, investigational, non-viral, gene therapy for #NMIBC.

Our CEO, Ron Cooper, is back on The Big Biz Show, discussing the latest developments at enGene and the significance of receiving the FDA’s RMAT designation for our investigational non- viral gene therapy, and what it means for the future of this disease.

This week, enGene was awarded the @biotecanada.bsky.social 2025 Gold Leaf Award for Biotech Company of the Year.

We are proud of the recognition of our team’s ongoing pursuit to drive innovation and mainstream non-viral, gene-based immunotherapy.

The DCAT Association Summit at Lugano centers patient needs to inspire meaningful forward-thinking. This week, Anthony Cheung, PhD, Co-Founder & CSO, will be presenting an overview of our ongoing LEGEND trial in patients with #NMIBC who face high treatment burden and unmet needs.

#DCATSummit

Next week, enGene will present at the 2025 @ascocancer.bsky.social Annual Meeting, sharing our trial in progress abstract for LEGEND, our ongoing clinical study for patients with high-risk, non-muscle invasive bladder cancer (NMIBC).

We hope to see you there!

#ASCO #ASCO25

Next week, Ron Cooper, CEO, will present at the Jefferies Global Healthcare Conference, providing an overview of enGene’s scientific approach, including updates on our novel, investigational, non-viral genetic medicine for #NMIBC.

Learn more here: engene.com/engene-to-pr...

#JefferiesHealthcare